1693-P: Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without Type 2 Diabetes
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1693-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von MELISSA THOMAS und 5 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction and Objective: In a Phase 2 study (NCT06124807), mazdutide (MAZ), a GLP-1 and glucagon receptor agonist, significantly reduced body weight by up to 22.3% and hemoglobin A1c (HbA1c) by up to 0.6% at 48 weeks among adults with overweight and obesity without T2D. Biomarkers of beta-cell function and insulin sensitivity were assessed to further explore mechanisms by which MAZ influences glycemic control.
Methods
Adults (N=179) with a BMI of ≥30 (or ≥27 kg/m2 with weight-related comorbidities) were assigned to MAZ (3/6, 10, or 16 mg) or placebo (PBO). Participants assigned to MAZ 3/6 mg escalated from 3 to 6 mg at week 32. Fasting biomarker changes from baseline to 48 weeks were assessed with mixed model for repeated measures. Homeostatic model assessments of insulin resistance (HOMA2-IR) and beta-cell function (HOMA2-B) were calculated with fasting glucose and insulin.
Results
MAZ was associated with PBO-adjusted reductions of up to 10.1 mg/dL in fasting glucose and up to 54.1% in fasting insulin (both p<0.001). HOMA2-IR was reduced by up to 41.6% with MAZ vs a 2.4% increase with PBO (p<0.001). Consistent with improved insulin sensitivity, adiponectin and IGFBP-2 increased by up to 34.3% and 50.2% with MAZ, respectively (vs 6.2% reduction and 5.3% increase with PBO, respectively; both p<0.001). FGF21, a marker of hepatic insulin sensitivity, declined by up to 50.7% with MAZ vs 22.8% with PBO (p<0.05). Intact proinsulin decreased by up to 32.5% with MAZ vs 8.3% with PBO, and fasting glucagon decreased by up to 88.6% vs 16.6% with PBO (both p<0.001). HOMA2-B, a marker of beta-cell function, did not consistently change with MAZ in these participants without T2D.
Conclusion
Treatment of people with obesity without T2D with MAZ was associated with improvements not only in body weight and HbA1c, but also in markers of insulin sensitivity. Disclosure M. Thomas: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. A.K. Weideman: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. T. Coskun: Employee; Current; Eli Lilly and Company. A. Haupt: Employee; Ended; Lilly. Stock/Shareholder; Ended; Lilly. O. Ferreira Galvao de Araujo: Employee; Current; Eli Lilly and Company. K.J. Mather: Employee; Current; Eli Lilly and Company.
Zitieren
APA
THOMAS, M., WEIDEMAN, A. M. K., COSKUN, T., HAUPT, A., ARAUJO, O. F. G. D., & MATHER, K. J. (2026). 1693-P: Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without Type 2 Diabetes. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1693-p
Vancouver
THOMAS M, WEIDEMAN AMK, COSKUN T, HAUPT A, ARAUJO OFGD, MATHER KJ. 1693-P: Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without Type 2 Diabetes. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1693-p
BibTeX
@article{THOMAS2026,
author = {THOMAS, MELISSA and WEIDEMAN, ANN MARIE K. and COSKUN, TAMER and HAUPT, AXEL and ARAUJO, OLIMPIA FERREIRA GALVAO DE and MATHER, KIEREN J.},
title = {1693-P: Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without Type 2 Diabetes},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1693-p}
}
EUVIMED